Table 2.
Dentin Hypersensitivity (DH) Measured by Visual Analogue Scale (VAS) (100 mm Scale) at Pretreatment Visit and on Post-Treatment Days 10, 30, 60, and 90
| Post-treatment | ||||||
|---|---|---|---|---|---|---|
| Pretreatment | Immediately post-treatment | Day 10 | Day 30 | Day 60 | Day 90 | |
| LLL | 48±27.90a | 24.59±24.59 (−48.8%) | 20.75±21.19b (−56.8%) | 14.10±16.04c (−70.6%) | 14.43±18.79 (−69.9%) | 13.43±22.94 (−72.0%) |
| DP | 54.90±33.49a | 35.12±35.12 (−36.0%) | 25.95±28.6b (−52.7%) | 20.70±23.94c (−62.3%) | 20.42±27.27 (−62.8%) | 19±29.05 (−65.4%) |
| LLL+DP | 54.90±31.31a | 29.62±29.62 (−46.0%) | 29.55±30.12 (−46.2%) | 28.11±28.47c (−48.8%) | 24.65±24.14 (−55.1%) | 24.92±28.57 (−54.6%) |
| DP+LLL | 60.09±29.73a | 39.19±39.19 (−34.8%) | 35.72±32.24 (−40.6%) | 23.03±24.14c (−61.7%) | 20.55±21.78 (−65.8%) | 18.24±23.14 (−69.6%) |
| Placebo | 37.91±20.26 | 36.82±36.82b (−2.8%) | 41.14±18.94d (+8.5%) | 41±21.05 (+8.2%) | 40.70±20.47 (+7.4%) | 40.85±19.83 (+7.8%) |
Data expressed as mean±SD (% change with respect to pretreatment score)
Bonferroni-vorrected Wilcoxon signed ranks test was used for comparisons.
a
p<0.005 compared with immediately post-treatment, and post-treatment days 10, 30, 60, and 90.
b
p<0.005 compared with pretreatment.
c
p<0.005 compared with post-treatment day 10.
d
p<0.005 compared with immediately post-treatment.